Tipifarnib

Generic Name: Tipifarnib

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₂₂Cl_₂N_₄O

CAS Number: 192185-72-1

Unique Ingredient Identifier: MAT637500A

Background: Tipifarnib (R-115777) is a substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer. It belongs to the family of drugs called farnesyltransferase inhibitors. It is also called Zarnestra. In June 2005, the FDA issued a Not Approvable Letter for Zarnestra.

Indication: Investigated for use/treatment in colorectal cancer, leukemia (myeloid), pancreatic cancer, and solid tumors.

Clinical Trials

Tipifarnib in Subjects With Myelodysplastic Syndromes

Phase 2

Terminated

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Tipifarnib

First Posted Date: 2016-05-20

Last Posted Date: 2024-07-31

Lead Sponsor: Kura Oncology, Inc.

Target Recruit Count: 16

Registration Number: NCT02779777

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States

Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma

Phase 2

Conditions: Urothelial Carcinoma

Interventions: Drug: tipifarnib

First Posted Date: 2015-08-28

Last Posted Date: 2022-03-08

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 19

Registration Number: NCT02535650

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy

Phase 2

Completed

Conditions: Relapsed or Refractory Peripheral T-Cell Lymphoma

Interventions: Drug: Tipifarnib

First Posted Date: 2015-06-08

Last Posted Date: 2024-06-26

Lead Sponsor: Kura Oncology, Inc.

Target Recruit Count: 65

Registration Number: NCT02464228

Locations: 🇪🇸
Hospital Universitari Vall d'Hebron, Barcelona, Spain
🇺🇸
Stanford University Medical Center, Palo Alto, California, United States
🇪🇸
Institut Catala d'Oncologia de Girona, Girona, Spain

and more 10 locations

Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations

Phase 2

Completed

Conditions: Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
HRAS Mutant Tumor
Thyroid Cancer
Other Squamous Cell Carcinoma (SCC) With HRAS Mutant Tumor

Interventions: Drug: Tipifarnib

First Posted Date: 2015-03-10

Last Posted Date: 2024-07-11

Lead Sponsor: Kura Oncology, Inc.

Target Recruit Count: 63

Registration Number: NCT02383927

Locations: 🇺🇸
Wihship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸
Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma, United States
🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

and more 32 locations

Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 1

Completed

Conditions: Adult Gliosarcoma
Adult Giant Cell Glioblastoma
Adult Glioblastoma

Interventions: Drug: Tipifarnib
Radiation: External Beam Radiation Therapy
Drug: Temozolomide
Other: Laboratory Biomarker Analysis

First Posted Date: 2014-08-28

Last Posted Date: 2014-12-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 19

Registration Number: NCT02227901

Locations: 🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States

Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders

Phase 1

Completed

Conditions: Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Chronic Myelomonocytic Leukemia
Recurrent Disease
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
Accelerated Phase of Disease
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Chronic Phase of Disease

Interventions: Other: Laboratory Biomarker Analysis
Drug: Tipifarnib

First Posted Date: 2014-08-07

Last Posted Date: 2018-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 31

Registration Number: NCT02210858

Locations: 🇺🇸
Stanford Cancer Institute, Palo Alto, California, United States
🇺🇸
University of Rochester, Rochester, New York, United States

Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Adult Acute Monoblastic Leukemia
Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
Adult Acute Megakaryoblastic Leukemia
Adult Acute Myeloid Leukemia With Maturation
Adult Erythroleukemia
Secondary Acute Myeloid Leukemia
Adult Acute Monocytic Leukemia
Adult Acute Myeloid Leukemia With Minimal Differentiation
Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1

Interventions: Drug: Tipifarnib
Other: Laboratory Biomarker Analysis

First Posted Date: 2011-05-26

Last Posted Date: 2015-04-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 21

Registration Number: NCT01361464

Locations: 🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

and more 4 locations

Efficacy and Safety of the Farnesyl-transferase Inhibitor (Tipifarnib) in Mantle Cell Lymphoma

Phase 2

Terminated

Conditions: Mantle Cell Lymphoma

Interventions: Drug: ZARNESTRA (Tipifarnib)

First Posted Date: 2009-02-19

Last Posted Date: 2018-08-23

Lead Sponsor: Lymphoma Study Association

Target Recruit Count: 11

Registration Number: NCT00847223

Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Secondary Acute Myeloid Leukemia
Adult Acute Myelomonocytic Leukemia (M4)
Untreated Adult Acute Myeloid Leukemia
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monocytic Leukemia (M5b)

Interventions: Drug: tipifarnib
Drug: etoposide

First Posted Date: 2008-01-28

Last Posted Date: 2014-10-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 84

Registration Number: NCT00602771

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States

and more 2 locations

Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid Leukemia

Phase 2

Conditions: Acute Myeloid Leukemia

First Posted Date: 2007-08-03

Last Posted Date: 2009-08-14

Lead Sponsor: University of Bologna

Target Recruit Count: 72

Registration Number: NCT00510939

Locations: 🇮🇹
Istituto di Ematologia "L e A Seragnoli" Policlinico S.Orsola-Malpighi, Bologna, Italy

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy